NCT06792799View on ClinicalTrials.gov

Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Autoimmune DiseasesSystemic Lupus ErthematosusMulti-Drug Resistant Nephrotic SyndromeIgAN - IgA Nephropathy
Interventions
BIOLOGICAL

anti-CD19/BCMA CAR NK cells (KN5601)

"Patients will receive Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) on day -5, -4, and -3. Multiple doses of anti-CD19 CAR NK cells (KN5601) will infused in each group using the 3 + 3 dose-escalation strategy."

Trial Locations (1)

310052

RECRUITING

Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000, Hangzhou

All Listed Sponsors
lead

The Children's Hospital of Zhejiang University School of Medicine

OTHER